Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 4,091,654 |
|
|||||
| News | - | ||||||
| Day High | 1.995 | Low High |
|||||
| Day Low | 1.87 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Geron Corp | GERN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.07 | 3.63% | 2.00 | 18:56:42 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.92 | 1.87 | 1.995 | 1.99 | 1.93 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 11,410 | 4,091,654 | US$ 1.94 | US$ 7,924,866 | - | 1.68 - 3.84 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:56:42 | formt | 510 | US$ 2.00 | USD |
Geron Corp Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.08B | 543.06M | - | 596k | -141.9M | -0.26 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Geron News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GERN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.97 | 2.035 | 1.85 | 1.93 | 3,112,255 | 0.03 | 1.52% |
| 1 Month | 1.76 | 2.07 | 1.68 | 1.88 | 4,772,114 | 0.24 | 13.64% |
| 3 Months | 2.47 | 2.655 | 1.68 | 1.97 | 5,492,934 | -0.47 | -19.03% |
| 6 Months | 3.30 | 3.735 | 1.68 | 2.52 | 5,541,920 | -1.30 | -39.39% |
| 1 Year | 2.35 | 3.84 | 1.68 | 2.65 | 6,399,254 | -0.35 | -14.89% |
| 3 Years | 1.87 | 3.84 | 0.9899 | 2.17 | 4,444,851 | 0.13 | 6.95% |
| 5 Years | 1.68 | 3.84 | 0.75 | 2.02 | 3,599,493 | 0.32 | 19.05% |
Geron Description
| Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. |
